X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
P-BCMA-ALLO1 is a Phase 1 investigational novel BCMA-targeted allogeneic CAR-T product candidate, targeting B-cell maturation antigen (BCMA) for the treatment of relapsed/refractory multiple myeloma.
Lead Product(s): P-BCMA-ALLO1,Rimiducid
Therapeutic Area: Oncology Product Name: P-BCMA-ALLO1
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2024
Details:
Under the agreement, Astellas gains a right of exclusive negotiation and first refusal to license one of Poseida's clinical stage programs, P-MUC1C-ALLO1, an allogeneic CAR-T cell therapy in development for multiple solid tumor indications.
Lead Product(s): P-MUC1C-ALLO1,Rimiducid
Therapeutic Area: Oncology Product Name: P-MUC1C-ALLO1
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Astellas Pharma
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 07, 2023
Details:
P-CD19CD20-ALLO1 is a first allogeneic dual CAR-T cell therapy which targets both CD19 and CD20 antigens for the treatment of relapsed or refractory B-cell malignancies and is being developed in partnership with Roche.
Lead Product(s): P-CD19CD20-ALLO1
Therapeutic Area: Oncology Product Name: P-CD19CD20-ALLO1
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
Under the agreement with Poseida, Roche to develop allogeneic CAR-T cell therapies for hematologic malignancies, including P-BCMA-ALLO1, an allogeneic CAR-T cell product to treat multiple myeloma, and P-CD19CD20-ALLO1 to treat B cell malignancies.
Lead Product(s): P-BCMA-ALLO1,Rimiducid
Therapeutic Area: Oncology Product Name: P-BCMA-ALLO1
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: $6,220.0 million Upfront Cash: $110.0 million
Deal Type: Collaboration August 03, 2022
Details:
The Phase 1 trial is an open label, multi-center, 3+3 dose-escalating study designed to assess the safety of P-PSMA-101 in up to 60 adult subjects with mCRPC. The primary objectives of this study are to determine the safety, efficacy, and maximum tolerated dose of P-PSMA-101.
Lead Product(s): P-PSMA-101,Rimiducid
Therapeutic Area: Oncology Product Name: P-PSMA-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2022
Details:
Under the terms of the agreement, the collaboration to initially develop up to six in vivo gene therapy programs including P-FVIII-101, utilizing Poseida's novel technology platforms and biodegradable nanoparticle technology, as well as certain emerging technologies.
Lead Product(s): P-FVIII-101
Therapeutic Area: Genetic Disease Product Name: P-FVIII-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: $3,600.0 million Upfront Cash: $45.0 million
Deal Type: Collaboration October 12, 2021
Details:
P-PSMA-101 is a High-Tscm Autologous CAR-T Targeting PSMA Producing Exceptionally Deep and Durable Responses in Castration-Resistant Metastatic Prostate Cancer.
Lead Product(s): P-PSMA-101,Rimiducid
Therapeutic Area: Oncology Product Name: P-PSMA-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2021
Details:
Highlights will include an early Data from ongoing P-BCMA-101, an autologous CAR-T product candidate in an ongoing Phase 1 dose expansion trial and Phase 2 trial, for relapsed/refractory multiple myeloma to treat patients with multiple myeloma.
Lead Product(s): P-BCMA-101
Therapeutic Area: Oncology Product Name: P-BCMA-101
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 24, 2021
Details:
U.S. FDA has lifted clinical hold on Poseida's Phase 1 study of P-PSMA-101 in metastatic castration-resistant prostate cancer and plans to resume the trial immediately. P-PSMA-101 is an autologous CAR-T therapeutic candidate in metastatic castration-resistant prostate cancer.
Lead Product(s): P-PSMA-101,Rimiducid
Therapeutic Area: Oncology Product Name: P-PSMA-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Collaboration leverages TScan's proprietary high-throughput TCR/Target discovery platform and poseida's proprietary allogeneic T cell approach to advance potential TCR-T treatments.
Lead Product(s): Allogeneic TCR-T cell therapies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: TScan Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
